- Previous Close
0.8623 - Open
0.8561 - Bid 0.8025 x 1000
- Ask 0.8639 x 1000
- Day's Range
0.8202 - 0.8600 - 52 Week Range
0.5200 - 1.5400 - Volume
787,854 - Avg. Volume
2,096,571 - Market Cap (intraday)
188.774M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 9, 2012
- 1y Target Est
4.83
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
vaxart.comRecent News: VXRT
View MorePerformance Overview: VXRT
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VXRT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VXRT
View MoreValuation Measures
Market Cap
196.12M
Enterprise Value
152.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.06
Price/Book (mrq)
2.45
Enterprise Value/Revenue
9.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.68%
Return on Equity (ttm)
-91.66%
Revenue (ttm)
13.93M
Net Income Avi to Common (ttm)
-75.66M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
62.59M
Total Debt/Equity (mrq)
28.91%
Levered Free Cash Flow (ttm)
-31.74M
Research Analysis: VXRT
View MoreCompany Insights: VXRT
VXRT does not have Company Insights